TG Therapeutics Inc (TGTX)
Return on total capital
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 41,929 | 25,677 | -192,839 | -344,770 | -273,594 |
| Long-term debt | US$ in thousands | 244,429 | 100,118 | 71,135 | 66,788 | 7,716 |
| Total stockholders’ equity | US$ in thousands | 222,364 | 160,502 | 58,587 | 237,153 | 519,350 |
| Return on total capital | 8.98% | 9.85% | -148.66% | -113.43% | -51.91% |
December 31, 2024 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $41,929K ÷ ($244,429K + $222,364K)
= 8.98%
TG Therapeutics Inc's return on total capital has shown a significant improvement from negative figures in the previous years to positive returns in the most recent years. The company experienced a negative return on total capital of -51.91% in December 2020, which worsened to -113.43% by December 2021, and further deteriorated to -148.66% by December 2022. However, there was a notable turnaround in December 2023 and December 2024, with positive returns of 9.85% and 8.98% respectively. This positive trend indicates that the company has been able to generate more profits relative to the total capital invested, demonstrating better efficiency and profitability in its operations in the later years.
Peer comparison
Dec 31, 2024